Merck Announces Data For V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults
Merck & Co., Inc. +0.28%
Merck & Co., Inc. MRK | 106.64 | +0.28% |
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Results build on the data supporting the clinical profile of V116 for adults